🟢 Strong Evidence
The World Health Organization (WHO) has added the first molecular diagnostic test for Bundibugyo virus (BDBV) to its Emergency Use Listing (EUL), marking a critical step in outbreak response. The test identifies viral genetic material in blood samples, enabling rapid and accurate confirmation of infection during the largest recorded outbreak of Ebola disease caused by BDBV.
Key takeaways
- WHO’s Emergency Use Listing now includes the first diagnostic test for Bundibugyo virus (BDBV), approved to rapidly identify genetic material in blood samples
- The approval follows WHO Director-General Dr Tedros Adhanom Ghebreyesus’s declaration of a public health emergency of international concern on 17 May 2026 and comes amid the largest documented BDBV outbreak affecting the Democratic Republic of the Congo and Uganda
- The listing accelerates access to quality-assured diagnostic tools for low- and middle-income countries, supporting early case detection and effective outbreak containment
Emergency approval process prioritises speed without compromising standards
WHO’s Emergency Use Listing procedure evaluates diagnostic quality, safety, and performance against international standards while addressing the urgent needs of resource-limited settings. According to Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data, timely access to validated diagnostic tests is essential during rapidly evolving outbreaks. “During a fast-moving outbreak, timely access to quality-assured diagnostic tests can make a critical difference in containing transmission,” Dr Nakatani stated. The EUL mechanism enables United Nations procurement agencies and governments to make evidence-based decisions about product adoption in public health emergencies.
The approval timeline demonstrates the urgency of the outbreak response. WHO launched a formal call for diagnostic test manufacturers to submit applications for Emergency Use Listing less than two weeks after Dr Tedros declared the public health emergency, compressing what is normally a longer evaluation process without sacrificing safety or accuracy standards.
Timeline of WHO response to Bundibugyo virus outbreak
Key milestones from outbreak declaration to diagnostic approval, May–July 2026
Source: WHO Emergency Response Timeline, 2026 | Georgian Medical Journal News
Rapid diagnostic testing critical for outbreak containment in DRC and Uganda
Molecular diagnostic testing is foundational to outbreak response, enabling clinicians to confirm BDBV infection within hours rather than days. Early identification supports rapid isolation of cases, contact tracing, and targeted clinical management—interventions that slow transmission chains. The test’s approval is particularly significant for the Democratic Republic of the Congo and Uganda, where healthcare infrastructure often faces resource constraints. Access to validated diagnostics directly supports global health emergency response capacity in resource-limited settings.
The availability of a quality-assured diagnostic tool also strengthens disease surveillance networks. Real-time case confirmation enables epidemiologists to track outbreak evolution, identify high-risk populations, and allocate clinical and preventive resources more efficiently. For countries with limited laboratory capacity, WHO’s EUL approval signals that the test meets rigorous international performance standards, reducing barriers to adoption and deployment.
Balancing speed with evidence in public health emergencies
WHO’s Emergency Use Listing process reflects the tension between rapid response and safety assurance during health crises. The EUL procedure assesses available evidence on diagnostic quality, safety, and performance—including sensitivity, specificity, and reliability in field settings—while maintaining international standards. This approach recognises that delayed access to validated tools can cost lives, but unvalidated products can cause harm through misdiagnosis and wasted resources.
The BDBV diagnostic approval demonstrates how WHO coordinates global procurement decisions. By listing the test, WHO provides governments and UN agencies such as UNICEF with authoritative evidence to guide purchasing decisions and supply chain management during emergencies. This reduces duplication of effort and ensures that resources flow to genuinely validated, field-appropriate tools. Clinical updates on emerging diagnostic approvals remain essential information for healthcare systems responding to novel threats.
WHO’s Emergency Use Listing approval of the first molecular diagnostic test for Bundibugyo virus accelerates access to quality-assured testing tools during the largest documented outbreak of BDBV, enabling rapid case confirmation and effective outbreak response in the Democratic Republic of the Congo and Uganda.
— Dr Yukiko Nakatani, WHO Assistant Director-General for Health Systems, Access and Data (WHO, July 2026)
What this means
Frequently asked questions
What is the Bundibugyo virus and how does it differ from other Ebola species?
Bundibugyo virus (BDBV) is one of six known species of Ebola virus, first identified in Uganda in 2007. According to WHO’s Ebola fact sheet, BDBV causes disease in humans but has historically been associated with smaller outbreaks than other species. The current outbreak in the Democratic Republic of the Congo is the largest BDBV outbreak on record, making rapid diagnostic tools especially important for outbreak control.
How does molecular diagnostic testing detect Bundibugyo virus?
Molecular tests, such as reverse transcription polymerase chain reaction (RT-PCR), identify viral genetic material (RNA) in blood samples. The approved WHO test detects BDBV genetic sequences with high sensitivity and specificity, enabling confirmation of infection typically within hours. This approach is more rapid and specific than antigen detection or serology, making it ideal for outbreak response when speed is critical.
What is WHO’s Emergency Use Listing and why is it important?
WHO’s Emergency Use Listing (EUL) is a mechanism that enables rapid evaluation and approval of medical products during public health emergencies. It ensures that products meet minimum standards for quality, safety, and performance while accelerating access in resource-limited settings. The EUL supports procurement decisions by UN agencies and governments, reducing bureaucratic delays without sacrificing evidence-based safety assurance.
As the BDBV outbreak continues across the Democratic Republic of the Congo and Uganda, the availability of WHO-approved diagnostic testing strengthens the foundation of outbreak response. Early case detection remains the cornerstone of transmission control, and the approval of this first diagnostic test removes a critical bottleneck in response capabilities. Future efforts will focus on ensuring equitable geographic distribution of diagnostic capacity and supporting laboratory networks in affected countries to translate approval into real-world testing availability.
Was this article helpful?
Related Coverage
